NUS researchers develop world’s first blood test for real-time monitoring of cancer treatment success

A team of researchers from the NUS Department of Biomedical Engineering and Institute for Health Innovation & Technology has developed a novel blood test called ExoSCOPE that could tell doctors whether cancer treatment is working for a patient, within 24 hours after the treatment. This will enable doctors to customise the treatment plan to improve patients’ chances of recovery.

Liquid biopsy for colorectal cancer could guide therapy for tumors

A new study from Washington University School of Medicine in St. Louis demonstrates that a liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumor. Such a biopsy can detect lingering disease and could serve as a guide for deciding whether a patient should undergo further treatments.

Cancer Research Institute and The Mark Foundation for Cancer Research Launch Collaboration to Evaluate Liquid Biopsy for More Accurate and Rapid Assessment of Lung Cancer Patient Response to Immunotherapy

The Cancer Research Institute (CRI) and The Mark Foundation for Cancer Research have launched a clinical trial that aims to demonstrate the utility of a novel, ultra-sensitive biomarker-directed blood test, or liquid biopsy, in assessing cancer patient responses to immunotherapy.

JNCCN Study Explores if Insurance is Keeping Pace with Trends in Targeted Cancer Therapy

New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.” The researchers found coverage rate rose from 0% to 38% in three years. The policies also increased in scope from 2017-2019, going from one cancer type to 12.

Biomarker test highly accurate in detecting early kidney cancer

A novel liquid biopsy method can detect kidney cancers with high accuracy, including small, localized tumors which are often curable but for which no early detection method exists, say scientists from Dana-Farber Cancer Institute.
The report in Nature Medicine suggests that if validated in larger trials and applied widely, the non-invasive test could find more early kidney cancers when they haven’t spread, thus reducing the mortality of the disease.